SCHEMBL233483

SCHEMBL233483

N=C(N)SCCN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL524425 0.97
Bromide SCHEMBL2470982 0.97
Bromide SCHEMBL29096722 0.94
Bromide SCHEMBL1649333 0.94
Sulfuric Acid SCHEMBL4408205 0.87 CYP1A2 (0.76)
SCHEMBL9197363 0.82
Bromide SCHEMBL4434174 0.80 CYP1A2 (0.95)
Bromide SCHEMBL17747992 0.80 HRH4 (1.00)
SCHEMBL29096739 0.75
SCHEMBL9193111 0.75 CYP1A2 (0.71)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 548 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4744663-A2 SKIN COMPOSITION Eaderm Co., Ltd. (JP) 2026-05-20 EP claimed
WO-2026090542-A1 BETA-AMINO-ESTER AND BETA-THIOL-ESTER CONTAINING POLYMERS FOR DRUG DELIVERY AND PHARMACEUTICAL USES EMORY UNIVERSITY (US) 2026-04-30 WO claimed
EP-4659023-A1 METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY Immusmol SAS (FR) 2025-12-10 EP claimed
WO-2024224296-A2 TARGETED PHARMACEUTICAL COMPOSITIONS TO TREAT NEUROLOGICAL CONDITIONS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2024-10-31 WO claimed
WO-2024161038-A1 METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY IMMUSMOL SAS (FR) 2024-08-08 WO claimed
CN-118079006-A Skin composition 国立大学法人东京医科齿科大学 2024-05-28 CN claimed
EP-4277592-A1 TOPICAL COMPOSITION Liliger Ltd (IL) 2023-11-22 EP claimed
EP-3473710-B1 SACCHARIFICATION REACTION SOLUTION, SACCHARIFYING ENZYME COMPOSITION, SUGAR PRODUCTION METHOD, AND ETHANOL PRODUCTION METHOD NISSAN CHEMICAL CORP (JP) 2023-09-27 EP claimed
CN-116685302-A Topical compositions 利勒格有限公司 2023-09-01 CN claimed
US-20220331389-A1 SKIN COMPOSITION EADERM CO., LTD. (JP) 2022-10-20 US claimed
US-6811965-B2 REPERFUSION SOLUTION FOR USE IN THE PRESERVATION OF ORGAN TISSUE HERMACELL PERFUSION, INC. 2004-11-02 US claimed
US-20040072809-A1 Antiinflammatory agents; analgesics; dilation; reducing pressure; therapy for vision defects OMEROS CORPORATION 2004-04-15 US claimed
WO-2004010894-A2 OPHTHALMOLOGIC IRRIGATION SOLUTIONS AND METHOD OMEROS CORPORATION (US) 2004-02-05 WO claimed
US-20030104348-A1 Kidney perfusion solution containing nitric oxide donor HERMACELL PERFUSION, INC. 2003-06-05 US claimed
WO-2001065935-A1 KIDNEY PERFUSION SOLUTION CONTAINING NITRIC OXIDE DONOR VODOVOTZ YORAM (US) 2001-09-13 WO claimed
EP-0743574-B1 Migration imaging members XEROX CORP (US) 2000-12-27 EP claimed
EP-0743573-B1 Method for obtaining image contrast migration imaging members XEROX CORP (US) 2000-09-06 EP claimed
EP-0426100-B1 Stabilized enzyme compositions ABBOTT LAB (US) 1994-12-14 EP claimed
CN-1095710-A Enzyme Inhibitors WELLCOME FOUND (GB) 1994-11-30 CN claimed
EP-0245669-B1 Pharmaceutical preparation for preventing damage to living cells by free radicals, or for increasing the efficacy of organic sulphur compounds, and process for increasing the life span of isolated organs FLOERSHEIM GEORG L (CH) 1993-12-01 EP claimed